Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

Young National Society Ambassadors

Early-career ambassadors from national societies who liaise with EHA and the Young EHA Committee on different projects.

Read more

ESID-EHA-SIOPE Focused Symposium 2025

Explore the interplay of immunodeficiency, hematologic conditions, and pediatric cancer at a unique, collaborative symposium. Dates: November 18–20, 2025
Location: Vienna, Austria

Abstract submission is open until 23:59 (CEST) on June 10, 2025.

Read more

EHA & ERN-EuroBloodNet Spotlight on Congenital Bone Marrow Failure (BMF) Syndromes Webinars

Register now on the ERN-EuroBloodNet website 

EHA & ERN-EuroBloodNet Spotlight on Congenital Bone Marrow Failure (BMF) Syndromes is an accredited European online educational program designed for healthcare professionals. It's jointly organized by EHA and ERN-EuroBloodNet.

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more